+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Long-acting Anti-HIV Drugs Market - Global Forecast 2026-2032- Product Image
Long-acting Anti-HIV Drugs Market - Global Forecast 2026-2032- Product Image
Sale

Long-acting Anti-HIV Drugs Market - Global Forecast 2026-2032

  • Report

  • 190 Pages
  • September 2026
  • Region: Global
  • 360iResearch™
  • ID: 6118869
UP TO OFF until Jan 01st 2027
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Long-acting Anti-HIV Drugs Market is projected to reach USD 445.10 Million in 2026. It is expected to continue growing at a CAGR of 20.43%, reaching USD 1.38 Billion by 2032.

Long-Acting Anti-HIV Drugs: Executive Summary

Long-acting anti-HIV drugs are reshaping HIV prevention and treatment by reducing the frequency of dosing compared with daily oral regimens. The category includes extended-release injectable antiretrovirals and other formulations designed to support sustained drug exposure. Its development is closely linked to adherence challenges, differentiated patient needs, healthcare access, regulatory requirements, and the continuing objective of expanding durable viral suppression and prevention coverage.

Dosing Innovation Is Reframing HIV Care Delivery

The transition from daily tablets toward longer-interval administration is changing how HIV services are organized. Clinical workflows must accommodate initiation protocols, injection scheduling, follow-up, storage, administration, and management of missed appointments. Long-acting options may reduce daily treatment burden for some people, but they also make continuity of care, timely re-dosing, patient selection, and resistance-risk management especially important. Successful implementation therefore depends on coordinated clinical, pharmacy, laboratory, and community-support systems.

Artificial Intelligence Strengthens Adherence and Safety Systems

Artificial intelligence can support long-acting anti-HIV drug programs by identifying patients at risk of missed visits, prioritizing outreach, optimizing appointment planning, and detecting patterns in laboratory and clinical records. It may also assist pharmacovigilance, medical-record review, and population-level service planning. These applications require representative data, transparent validation, privacy safeguards, clinician oversight, and controls against biased recommendations. AI should augment-not replace-shared decision-making and established clinical guidelines.

Regional Differences Center on Access, Infrastructure, and Delivery Models

North America is characterized by advanced specialist care, regulatory activity, and varied reimbursement environments. Europe combines strong public-health systems with country-level differences in procurement, guidelines, and service integration. Asia-Pacific includes highly diverse regulatory, clinical, and financing conditions, with implementation shaped by urban concentration and healthcare capacity. Latin America is influenced by public-sector procurement, treatment equity, and differences in supply continuity. The Middle East reflects varied national health systems and access pathways, while Africa places particular emphasis on scalable delivery, decentralized services, supply reliability, and reducing barriers to prevention and lifelong treatment.

Cross-Group Patterns Reveal Uneven Readiness for Long-Acting Care

ASEAN members face differing regulatory, financing, and healthcare-delivery capabilities, making regional harmonization and adaptable service models valuable. BRICS economies combine substantial scientific and manufacturing capabilities with wide variation in access, affordability, and public-health infrastructure. The European Union benefits from coordinated policy dialogue but retains national differences in reimbursement and implementation. G7 systems generally have strong clinical infrastructure and data capacity, alongside scrutiny of affordability and health equity. GCC countries often have comparatively well-resourced healthcare systems but differing population profiles and service-access arrangements. NATO members span diverse health systems, so defense and civilian health priorities should not be treated as interchangeable.

Country Contexts Shape Uptake and Program Design

Australia, Canada, France, Germany, Italy, Japan, South Korea, Spain, the United Kingdom, and the United States generally have established specialist HIV services, with adoption influenced by reimbursement, clinical guidance, and delivery capacity. Brazil, Mexico, India, China, and Russia differ substantially in public-health organization, regulatory pathways, and geographic access. Country programs should assess local treatment guidelines, procurement processes, laboratory networks, cold-chain or storage requirements, injection capacity, and mechanisms for reaching underserved populations rather than relying on a uniform deployment model.

Prioritize Patient Fit, Reliable Follow-Up, and Equitable Implementation

Industry leaders should build evidence around patient preferences, real-world persistence, missed-dose management, resistance prevention, and outcomes across diverse populations. Partnerships with public-health agencies and community organizations can improve trust, appointment continuity, and reach. Operational plans should include trained providers, dependable supply and storage, reminder and outreach systems, transparent affordability strategies, and clear referral pathways. Digital and AI tools should be governed through privacy, cybersecurity, bias monitoring, and human-review standards. Implementation metrics should track initiation, on-time administration, retention, viral suppression, prevention coverage, adverse events, and equity across population groups.

Methodology Combines Evidence Review With Contextual Health-System Analysis

This executive summary uses the defined market scope of long-acting anti-HIV drugs and synthesizes verified, data-backed themes from established clinical, regulatory, public-health, and implementation evidence. The assessment considers formulation characteristics, adherence and delivery requirements, regional and country health-system conditions, policy environments, and responsible AI applications. It intentionally excludes market estimates, market sizing, market shares, forecasts, and unsupported company-specific claims. Conclusions are framed as implementation and strategic insights rather than numerical market projections.

Long-Acting Anti-HIV Drugs Require Integrated Clinical and System Readiness

Long-acting anti-HIV drugs offer an important approach to reducing daily treatment burden and supporting prevention and treatment continuity for appropriately selected patients. Their impact will depend less on formulation innovation alone than on reliable follow-up, equitable access, provider capability, resistance-risk management, and alignment with local health systems. Leaders that combine patient-centered evidence, resilient delivery infrastructure, responsible data use, and community engagement will be better positioned to translate long-acting therapy into durable public-health benefits.

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Definition
1.3. Market Segmentation & Coverage
1.4. Years Considered for the Study
1.5. Currency Considered for the Study
1.6. Language Considered for the Study
1.7. Key Stakeholders
2. Research Methodology
2.1. Introduction
2.2. Research Design
2.2.1. Primary Research
2.2.2. Secondary Research
2.3. Research Framework
2.3.1. Qualitative Analysis
2.3.2. Quantitative Analysis
2.4. Market Size Estimation
2.4.1. Top-Down Approach
2.4.2. Bottom-Up Approach
2.5. Data Triangulation
2.6. Research Outcomes
2.7. Research Assumptions
2.8. Research Limitations
3. Executive Summary
3.1. Introduction
3.2. CXO Perspective
3.3. New Revenue Opportunities
3.4. Next-Generation Business Models
3.5. Industry Roadmap
4. Market Overview
4.1. Introduction
4.2. Industry Ecosystem & Value Chain Analysis
4.2.1. Supply-Side Analysis
4.2.2. Demand-Side Analysis
4.2.3. Stakeholder Analysis
4.3. Market Dynamics
4.3.1. Key Drivers
4.3.2. Key Restraints
4.3.3. Key Opportunities
4.3.4. Key Challenges
4.4. Porter’s Five Forces Analysis
4.5. PESTLE Analysis
4.6. Market Outlook
4.6.1. Near-Term Market Outlook (0-2 Years)
4.6.2. Medium-Term Market Outlook (3-5 Years)
4.6.3. Long-Term Market Outlook (5-10 Years)
4.7. Go-to-Market Strategy
5. Market Insights
5.1. Consumer Insights & End-User Perspective
5.2. Consumer Experience Benchmarking
5.3. Opportunity Mapping
5.4. Distribution Channel Analysis
5.5. Pricing Trend Analysis
5.6. Regulatory Compliance & Standards Framework
5.7. ESG & Sustainability Analysis
5.8. Disruption & Risk Scenarios
5.9. Return on Investment & Cost-Benefit Analysis
6. Cumulative Impact of Artificial Intelligence 2026
7. Long-acting Anti-HIV Drugs Market, by Product Type
7.1. Introduction
7.2. Implant
7.2.1. Biodegradable
7.2.2. Non-Biodegradable
7.3. Injectable
7.3.1. Intramuscular
7.3.2. Subcutaneous
8. Long-acting Anti-HIV Drugs Market, by Mode Of Action
8.1. Introduction
8.2. Integrase Inhibitor
8.3. Protease Inhibitor
8.4. Reverse Transcriptase Inhibitor
9. Long-acting Anti-HIV Drugs Market, by Therapy Area
9.1. Introduction
9.2. Prevention
9.3. Treatment
10. Long-acting Anti-HIV Drugs Market, by Dosing Frequency
10.1. Introduction
10.2. Bi-Monthly
10.3. Monthly
10.4. Quarterly
11. Long-acting Anti-HIV Drugs Market, by Treatment Regimen
11.1. Introduction
11.2. Combination
11.2.1. Three Drug Regimen
11.2.2. Two Drug Regimen
11.3. Monotherapy
12. Long-acting Anti-HIV Drugs Market, by Patient Type
12.1. Introduction
12.2. Adult
12.3. Pediatric
13. Long-acting Anti-HIV Drugs Market, by Distribution Channel
13.1. Introduction
13.2. Offline
13.3. Online
14. Long-acting Anti-HIV Drugs Market, by Region
14.1. Introduction
14.2. Asia-Pacific
14.3. North America
14.4. Latin America
14.5. Europe
14.6. Middle East
14.7. Africa
15. Long-acting Anti-HIV Drugs Market, by Group
15.1. Introduction
15.2. ASEAN
15.3. GCC
15.4. European Union
15.5. BRICS
15.6. G7
15.7. NATO
16. Long-acting Anti-HIV Drugs Market, by Country
16.1. Introduction
16.2. United States
16.3. Canada
16.4. Mexico
16.5. Brazil
16.6. United Kingdom
16.7. Germany
16.8. France
16.9. Russia
16.10. Italy
16.11. Spain
16.12. China
16.13. India
16.14. Japan
16.15. Australia
16.16. South Korea
17. Competitive Landscape
17.1. Market Share Analysis, 2025
17.2. Market Concentration Analysis, 2025
17.2.1. Concentration Ratio (CR)
17.2.2. Herfindahl Hirschman Index (HHI)
17.3. Recent Developments & Impact Analysis, 2025
17.4. Product Portfolio Analysis, 2025
17.5. Benchmarking Analysis, 2025
18. Company Profiles
18.1. Accord Healthcare Inc.
18.2. Amneal Pharmaceuticals, Inc.
18.3. Aurobindo Pharma Ltd.
18.4. Cipla Ltd.
18.5. Dr. Reddy's Laboratories Ltd.
18.6. Genentech, Inc.
18.7. Gilead Sciences, Inc.
18.8. Hetero Labs Limited
18.9. Johnson & Johnson
18.10. Lupin Limited
18.11. Merck & Co., Inc.
18.12. Mylan N.V.
18.13. Sun Pharmaceutical Industries Ltd.
18.14. Teva Pharmaceutical Industries Ltd.
18.15. Theratechnologies Inc.
18.16. Viatris Inc.
18.17. ViiV Healthcare Limited
19. Key Experts
LIST OF FIGURES
FIGURE 1. Global Long-acting Anti-HIV Drugs Market, Years Considered for the Study
FIGURE 2. Global Long-acting Anti-HIV Drugs Market, Research Design
FIGURE 3. Global Long-acting Anti-HIV Drugs Market, Research Framework
FIGURE 4. Global Long-acting Anti-HIV Drugs Market, Data Triangulation
FIGURE 5. Global Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
FIGURE 6. Global Long-acting Anti-HIV Drugs Market Size, by Product Type, 2025 vs 2032 (%)
FIGURE 7. Global Long-acting Anti-HIV Drugs Market Size, by Product Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 8. Global Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2025 vs 2032 (%)
FIGURE 9. Global Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 10. Global Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2025 vs 2032 (%)
FIGURE 11. Global Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 12. Global Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2025 vs 2032 (%)
FIGURE 13. Global Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 14. Global Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2025 vs 2032 (%)
FIGURE 15. Global Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 16. Global Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2025 vs 2032 (%)
FIGURE 17. Global Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 18. Global Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2025 vs 2032 (%)
FIGURE 19. Global Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 20. Global Long-acting Anti-HIV Drugs Market Size, by Region, 2025 vs 2032 (%)
FIGURE 21. Global Long-acting Anti-HIV Drugs Market Size, by Region, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 22. Global Long-acting Anti-HIV Drugs Market Size, by Group, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 23. Global Long-acting Anti-HIV Drugs Market Size, by Country, 2025 vs 2032 (%)
FIGURE 24. Global Long-acting Anti-HIV Drugs Market Size, by Country, 2025 vs 2026 vs 2032 (USD Million)
FIGURE 25. Global Long-acting Anti-HIV Drugs Market Share, by Key Player, 2025
LIST OF TABLES
TABLE 1. Global Long-acting Anti-HIV Drugs Market Segmentation & Coverage
TABLE 2. Global Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 3. Global Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 4. Global Implant Market Size, by Region, 2017-2032 (USD Million)
TABLE 5. Global Implant Market Size, by Group, 2017-2032 (USD Million)
TABLE 6. Global Implant Market Size, by Country, 2017-2032 (USD Million)
TABLE 7. Global Biodegradable Market Size, by Region, 2017-2032 (USD Million)
TABLE 8. Global Biodegradable Market Size, by Group, 2017-2032 (USD Million)
TABLE 9. Global Biodegradable Market Size, by Country, 2017-2032 (USD Million)
TABLE 10. Global Non-Biodegradable Market Size, by Region, 2017-2032 (USD Million)
TABLE 11. Global Non-Biodegradable Market Size, by Group, 2017-2032 (USD Million)
TABLE 12. Global Non-Biodegradable Market Size, by Country, 2017-2032 (USD Million)
TABLE 13. Global Injectable Market Size, by Region, 2017-2032 (USD Million)
TABLE 14. Global Injectable Market Size, by Group, 2017-2032 (USD Million)
TABLE 15. Global Injectable Market Size, by Country, 2017-2032 (USD Million)
TABLE 16. Global Intramuscular Market Size, by Region, 2017-2032 (USD Million)
TABLE 17. Global Intramuscular Market Size, by Group, 2017-2032 (USD Million)
TABLE 18. Global Intramuscular Market Size, by Country, 2017-2032 (USD Million)
TABLE 19. Global Subcutaneous Market Size, by Region, 2017-2032 (USD Million)
TABLE 20. Global Subcutaneous Market Size, by Group, 2017-2032 (USD Million)
TABLE 21. Global Subcutaneous Market Size, by Country, 2017-2032 (USD Million)
TABLE 22. Global Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 23. Global Integrase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 24. Global Integrase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 25. Global Integrase Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 26. Global Protease Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 27. Global Protease Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 28. Global Protease Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 29. Global Reverse Transcriptase Inhibitor Market Size, by Region, 2017-2032 (USD Million)
TABLE 30. Global Reverse Transcriptase Inhibitor Market Size, by Group, 2017-2032 (USD Million)
TABLE 31. Global Reverse Transcriptase Inhibitor Market Size, by Country, 2017-2032 (USD Million)
TABLE 32. Global Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 33. Global Prevention Market Size, by Region, 2017-2032 (USD Million)
TABLE 34. Global Prevention Market Size, by Group, 2017-2032 (USD Million)
TABLE 35. Global Prevention Market Size, by Country, 2017-2032 (USD Million)
TABLE 36. Global Treatment Market Size, by Region, 2017-2032 (USD Million)
TABLE 37. Global Treatment Market Size, by Group, 2017-2032 (USD Million)
TABLE 38. Global Treatment Market Size, by Country, 2017-2032 (USD Million)
TABLE 39. Global Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 40. Global Bi-Monthly Market Size, by Region, 2017-2032 (USD Million)
TABLE 41. Global Bi-Monthly Market Size, by Group, 2017-2032 (USD Million)
TABLE 42. Global Bi-Monthly Market Size, by Country, 2017-2032 (USD Million)
TABLE 43. Global Monthly Market Size, by Region, 2017-2032 (USD Million)
TABLE 44. Global Monthly Market Size, by Group, 2017-2032 (USD Million)
TABLE 45. Global Monthly Market Size, by Country, 2017-2032 (USD Million)
TABLE 46. Global Quarterly Market Size, by Region, 2017-2032 (USD Million)
TABLE 47. Global Quarterly Market Size, by Group, 2017-2032 (USD Million)
TABLE 48. Global Quarterly Market Size, by Country, 2017-2032 (USD Million)
TABLE 49. Global Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 50. Global Combination Market Size, by Region, 2017-2032 (USD Million)
TABLE 51. Global Combination Market Size, by Group, 2017-2032 (USD Million)
TABLE 52. Global Combination Market Size, by Country, 2017-2032 (USD Million)
TABLE 53. Global Three Drug Regimen Market Size, by Region, 2017-2032 (USD Million)
TABLE 54. Global Three Drug Regimen Market Size, by Group, 2017-2032 (USD Million)
TABLE 55. Global Three Drug Regimen Market Size, by Country, 2017-2032 (USD Million)
TABLE 56. Global Two Drug Regimen Market Size, by Region, 2017-2032 (USD Million)
TABLE 57. Global Two Drug Regimen Market Size, by Group, 2017-2032 (USD Million)
TABLE 58. Global Two Drug Regimen Market Size, by Country, 2017-2032 (USD Million)
TABLE 59. Global Monotherapy Market Size, by Region, 2017-2032 (USD Million)
TABLE 60. Global Monotherapy Market Size, by Group, 2017-2032 (USD Million)
TABLE 61. Global Monotherapy Market Size, by Country, 2017-2032 (USD Million)
TABLE 62. Global Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 63. Global Adult Market Size, by Region, 2017-2032 (USD Million)
TABLE 64. Global Adult Market Size, by Group, 2017-2032 (USD Million)
TABLE 65. Global Adult Market Size, by Country, 2017-2032 (USD Million)
TABLE 66. Global Pediatric Market Size, by Region, 2017-2032 (USD Million)
TABLE 67. Global Pediatric Market Size, by Group, 2017-2032 (USD Million)
TABLE 68. Global Pediatric Market Size, by Country, 2017-2032 (USD Million)
TABLE 69. Global Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 70. Global Offline Market Size, by Region, 2017-2032 (USD Million)
TABLE 71. Global Offline Market Size, by Group, 2017-2032 (USD Million)
TABLE 72. Global Offline Market Size, by Country, 2017-2032 (USD Million)
TABLE 73. Global Online Market Size, by Region, 2017-2032 (USD Million)
TABLE 74. Global Online Market Size, by Group, 2017-2032 (USD Million)
TABLE 75. Global Online Market Size, by Country, 2017-2032 (USD Million)
TABLE 76. Global Long-acting Anti-HIV Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 77. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 78. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 79. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 80. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 81. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 82. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 83. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 84. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 85. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 86. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 87. Asia-Pacific Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 88. North America Long-acting Anti-HIV Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 89. North America Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 90. North America Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 91. North America Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 92. North America Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 93. North America Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 94. North America Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 95. North America Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 96. North America Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 97. North America Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 98. North America Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 99. Latin America Long-acting Anti-HIV Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 100. Latin America Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 101. Latin America Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 102. Latin America Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 103. Latin America Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 104. Latin America Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 105. Latin America Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 106. Latin America Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 107. Latin America Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 108. Latin America Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 109. Latin America Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 110. Europe Long-acting Anti-HIV Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 111. Europe Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 112. Europe Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 113. Europe Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 114. Europe Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 115. Europe Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 116. Europe Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 117. Europe Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 118. Europe Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 119. Europe Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 120. Europe Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 121. Middle East Long-acting Anti-HIV Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 122. Middle East Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 123. Middle East Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 124. Middle East Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 125. Middle East Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 126. Middle East Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 127. Middle East Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 128. Middle East Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 129. Middle East Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 130. Middle East Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 131. Middle East Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 132. Africa Long-acting Anti-HIV Drugs Market Size, by Region, 2017-2032 (USD Million)
TABLE 133. Africa Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 134. Africa Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 135. Africa Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 136. Africa Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 137. Africa Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 138. Africa Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 139. Africa Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 140. Africa Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 141. Africa Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 142. Africa Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 143. Global Long-acting Anti-HIV Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 144. ASEAN Long-acting Anti-HIV Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 145. ASEAN Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 146. ASEAN Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 147. ASEAN Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 148. ASEAN Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 149. ASEAN Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 150. ASEAN Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 151. ASEAN Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 152. ASEAN Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 153. ASEAN Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 154. ASEAN Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 155. GCC Long-acting Anti-HIV Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 156. GCC Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 157. GCC Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 158. GCC Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 159. GCC Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 160. GCC Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 161. GCC Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 162. GCC Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 163. GCC Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 164. GCC Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 165. GCC Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 166. European Union Long-acting Anti-HIV Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 167. European Union Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 168. European Union Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 169. European Union Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 170. European Union Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 171. European Union Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 172. European Union Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 173. European Union Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 174. European Union Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 175. European Union Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 176. European Union Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 177. BRICS Long-acting Anti-HIV Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 178. BRICS Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 179. BRICS Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 180. BRICS Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 181. BRICS Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 182. BRICS Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 183. BRICS Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 184. BRICS Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 185. BRICS Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 186. BRICS Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 187. BRICS Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 188. G7 Long-acting Anti-HIV Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 189. G7 Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 190. G7 Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 191. G7 Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 192. G7 Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 193. G7 Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 194. G7 Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 195. G7 Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 196. G7 Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 197. G7 Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 198. G7 Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 199. NATO Long-acting Anti-HIV Drugs Market Size, by Group, 2017-2032 (USD Million)
TABLE 200. NATO Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 201. NATO Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 202. NATO Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 203. NATO Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 204. NATO Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 205. NATO Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 206. NATO Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 207. NATO Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 208. NATO Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 209. NATO Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 210. Global Long-acting Anti-HIV Drugs Market Size, by Country, 2017-2032 (USD Million)
TABLE 211. United States Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 212. United States Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 213. United States Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 214. United States Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 215. United States Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 216. United States Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 217. United States Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 218. United States Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 219. United States Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 220. United States Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 221. United States Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 222. Canada Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 223. Canada Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 224. Canada Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 225. Canada Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 226. Canada Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 227. Canada Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 228. Canada Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 229. Canada Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 230. Canada Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 231. Canada Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 232. Canada Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 233. Mexico Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 234. Mexico Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 235. Mexico Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 236. Mexico Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 237. Mexico Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 238. Mexico Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 239. Mexico Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 240. Mexico Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 241. Mexico Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 242. Mexico Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 243. Mexico Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 244. Brazil Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 245. Brazil Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 246. Brazil Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 247. Brazil Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 248. Brazil Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 249. Brazil Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 250. Brazil Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 251. Brazil Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 252. Brazil Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 253. Brazil Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 254. Brazil Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 255. United Kingdom Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 256. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 257. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 258. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 259. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 260. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 261. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 262. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 263. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 264. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 265. United Kingdom Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 266. Germany Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 267. Germany Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 268. Germany Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 269. Germany Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 270. Germany Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 271. Germany Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 272. Germany Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 273. Germany Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 274. Germany Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 275. Germany Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 276. Germany Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 277. France Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 278. France Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 279. France Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 280. France Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 281. France Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 282. France Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 283. France Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 284. France Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 285. France Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 286. France Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 287. France Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 288. Russia Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 289. Russia Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 290. Russia Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 291. Russia Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 292. Russia Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 293. Russia Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 294. Russia Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 295. Russia Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 296. Russia Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 297. Russia Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 298. Russia Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 299. Italy Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 300. Italy Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 301. Italy Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 302. Italy Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 303. Italy Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 304. Italy Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 305. Italy Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 306. Italy Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 307. Italy Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 308. Italy Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 309. Italy Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 310. Spain Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 311. Spain Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 312. Spain Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 313. Spain Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 314. Spain Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 315. Spain Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 316. Spain Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 317. Spain Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 318. Spain Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 319. Spain Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 320. Spain Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 321. China Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 322. China Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 323. China Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 324. China Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 325. China Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 326. China Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 327. China Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 328. China Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 329. China Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 330. China Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 331. China Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE 332. India Long-acting Anti-HIV Drugs Market Size, 2017-2032 (USD Million)
TABLE 333. India Long-acting Anti-HIV Drugs Market Size, by Product Type, 2017-2032 (USD Million)
TABLE 334. India Long-acting Anti-HIV Drugs Market Size, by Implant, 2017-2032 (USD Million)
TABLE 335. India Long-acting Anti-HIV Drugs Market Size, by Injectable, 2017-2032 (USD Million)
TABLE 336. India Long-acting Anti-HIV Drugs Market Size, by Mode Of Action, 2017-2032 (USD Million)
TABLE 337. India Long-acting Anti-HIV Drugs Market Size, by Therapy Area, 2017-2032 (USD Million)
TABLE 338. India Long-acting Anti-HIV Drugs Market Size, by Dosing Frequency, 2017-2032 (USD Million)
TABLE 339. India Long-acting Anti-HIV Drugs Market Size, by Treatment Regimen, 2017-2032 (USD Million)
TABLE 340. India Long-acting Anti-HIV Drugs Market Size, by Combination, 2017-2032 (USD Million)
TABLE 341. India Long-acting Anti-HIV Drugs Market Size, by Patient Type, 2017-2032 (USD Million)
TABLE 342. India Long-acting Anti-HIV Drugs Market Size, by Distribution Channel, 2017-2032 (USD Million)
TABLE

Companies Mentioned

  • Accord Healthcare Inc.
  • Amneal Pharmaceuticals, Inc.
  • Aurobindo Pharma Ltd.
  • Cipla Ltd.
  • Dr. Reddy's Laboratories Ltd.
  • Genentech, Inc.
  • Gilead Sciences, Inc.
  • Hetero Labs Limited
  • Johnson & Johnson
  • Lupin Limited
  • Merck & Co., Inc.
  • Mylan N.V.
  • Sun Pharmaceutical Industries Ltd.
  • Teva Pharmaceutical Industries Ltd.
  • Theratechnologies Inc.
  • Viatris Inc.
  • ViiV Healthcare Limited

Related Topics

Related Reports

HIV Drugs Market Report 2026 - Product Image

HIV Drugs Market Report 2026

  • Report
  • 250 Pages
  • Global
From
North America HIV Drugs Market Size, Share, Trends and Forecast by Drug Class, Distribution Channel, and Country, 2026-2034 - Product Image

North America HIV Drugs Market Size, Share, Trends and Forecast by Drug Class, Distribution Channel, and Country, 2026-2034

  • Report
  • 150 Pages
  • North America
From
Prophylactic HIV Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031) - Product Image

Prophylactic HIV Drugs - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

  • Report
  • 110 Pages
  • Global
From
Anti-Retroviral Drugs Market - Global Forecast 2026-2032 - Product Image

Anti-Retroviral Drugs Market - Global Forecast 2026-2032

  • Report
  • 194 Pages
  • Global
From
Anti-Retroviral Drugs - Global Strategic Business Report - Product Image

Anti-Retroviral Drugs - Global Strategic Business Report

  • Report
  • 280 Pages
  • Global
From
Copyright © 2002-2026 Research and Markets. All Rights Reserved.